PC
PCRX icon

Paulson & Co’s Pacira BioSciences PCRX Stock Holding History

Paulson & Co’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-350,000
Closed -$20.4M – 30
2022
Q2 		$20.4M Sell
350,000
-150,000
-30% -$9.83M 1.01% 19
2022
Q1 		$38.2M Sell
500,000
-1,205,599
-71% -$80.4M 1.17% 21
2021
Q4 		$103M Buy
1,705,599
+446,081
+35% +$24.6M 3.16% 8
2021
Q3 		$70.5M Sell
1,259,518
-13,643
-1% -$786K 2.01% 12
2021
Q2 		$77.3M Sell
1,273,161
-140,693
-10% -$8.91M 1.85% 16
2021
Q1 		$99.1M Hold
1,413,854
– – 2.28% 12
2020
Q4 		$84.6M Buy
1,413,854
+158,246
+13% +$9.27M 2.2% 13
2020
Q3 		$75.5M Sell
1,255,608
-34,333
-3% -$1.99M 2.35% 12
2020
Q2 		$67.7M Sell
1,289,941
-426,786
-25% -$17.8M 2.16% 13
2020
Q1 		$57.6M Hold
1,716,727
– – 2.2% 14
2019
Q4 		$77.8M Hold
1,716,727
– – 1.68% 14
2019
Q3 		$65.4M Buy
1,716,727
+757,730
+79% +$30.2M 1.31% 20
2019
Q2 		$41.7M Buy
958,997
+708,997
+284% +$30.1M 0.71% 28
2019
Q1 		$9.52M Buy
+250,000
New +$9.76M 0.2% 39

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.85B AUM 15.7% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Paulson & Co's PCRX Position: Q3 2022 in Review

Paulson & Co sold out of Pacira BioSciences (PCRX) in Q3 2022, closing a stake of 350,000 shares — an estimated $20.4M sold.

Paulson & Co first reported a position in PCRX in Q1 2019 and held it in 14 quarters. The position peaked at $103M in Q4 2021. 272 funds tracked by Wall St. Rank hold PCRX as of Q3 2022.

  • Paulson & Co reported no remaining Pacira BioSciences position as of Q3 2022 after selling out during the quarter.
  • Paulson & Co sold 350,000 Pacira BioSciences shares in Q3 2022, an estimated $20.4M.
  • Paulson & Co first reported a position in Pacira BioSciences in Q1 2019 and held it in 14 quarters.
  • Paulson & Co's Pacira BioSciences position peaked at $103M in Q4 2021.
  • 272 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2022.

Based on Paulson & Co's 13F filing for Q3 2022, filed 14 Nov 2022.